IMPACT OF HISTOLOGICAL TUMOR-FREE MARGIN (hTFM) AND RE-EXCISION ON SURVIVAL IN PRIMARY VULVAR CANCER WITH ADJACENT VULVAR INTRAEPITHELIAL NEOPLASIA (VIN III)

Author(s):  
Khayal Gasimli
Cancers ◽  
2022 ◽  
Vol 14 (2) ◽  
pp. 389
Author(s):  
Lauro Bucchi ◽  
Margherita Pizzato ◽  
Stefano Rosso ◽  
Stefano Ferretti

The aim of this review was an update of vulvar cancer incidence rates and trends and of all known and putative risk factors for the disease. The most recent incidence data were sought from official sources (WHO Cancer Incidence in Five Continents). To obtain an estimate of time trends in some areas, we compared data from Cancer Incidence in Five Continents with the few available studies that measured incidence using comparable methods. With respect to risk factors, a systematic PubMed search identified 1585 relevant articles published between 1980 and 2021. Abstracts and full texts were screened. Sixty-nine eligible original cohort and case-control studies were selected. Information was extracted using a PRISMA predesigned form. Nineteen risk factors, or risk factor categories, were investigated by two or more original studies. Solitary, unreplicated studies addressed the putative role of eight more factors. Recent advances have provided further evidence supporting the carcinogenic model centred on human papillomavirus infection with different defects of the immune function. Conversely, the model centred on the role of vulvar lichen sclerosus and the often associated differentiated vulvar intraepithelial neoplasia has continued to be epidemiologically understudied. More research on the association between these two conditions and vulvar cancer is a priority.


Tumor Biology ◽  
2000 ◽  
Vol 21 (2) ◽  
pp. 98-104 ◽  
Author(s):  
Lukas Hefler ◽  
Clemens Tempfer ◽  
Katrin Frischmuth ◽  
Georg Maenner ◽  
Nicole Concin ◽  
...  

2021 ◽  
Vol 17 (3) ◽  
pp. 114-120
Author(s):  
V. S. Levchenko ◽  
E. V. Grebenkina ◽  
N. A. Illarionova ◽  
E. N. Koroleva ◽  
S. V. Zinovyev ◽  
...  

Vulvar intraepithelial neoplasia (VIN) is the proliferation of atypical basal cells in the vulvar epithelium. The global VIN incidence has recently doubled; its incidence among white women under 35 years of age has almost tripled with a tendency for further growth. Such an increase in the number of usual-type VIN cases in young women is primarily attributed to infection with highly oncogenic human papillomavirus. The second type of dysplasia, namely differentiated VIN, is usually found in older women and is associated with chronic dystrophic diseases of the vulva, most frequently with lichen sclerosus of the vulva. VIN diagnosis is quite challenging; no screening programs for this disorder have been developed so far. Patients with VIN practice self-treatment for a long time, which aggravates their condition and might trigger the development of vulvar cancer. Several treatment options are currently available; however, their efficacy worldwide is not high.


2009 ◽  
Vol 101 (1) ◽  
pp. 27-31 ◽  
Author(s):  
R P de Bie ◽  
H P van de Nieuwenhof ◽  
R L M Bekkers ◽  
W J G Melchers ◽  
A G Siebers ◽  
...  

Author(s):  
Vivian de Oliveira Rodrigues Brum ◽  
Denise Gasparetti Drumond ◽  
Neila Maria de Góis Speck ◽  
Gabriel Duque Pannain ◽  
Giovana Moreira Bordim

Vulvar cancer is a recurrent subject in gynecological cancer. Vulvar Intraepithelial Neoplasia is known for being a precursor lesion of vulvar cancer and can be divided in three different subtypes: Low-grade Vulvar Intraepithelial Lesion (vulvar LSI), High-grade Vulvar Intraepithelial Lesion (vulvar HSIL) and Differentiated Vulvar Intraepithelial Neoplasia (dVIN). These subtypes differ in several aspects, and this article aims to present those differences in order to facilitate its treatment and the final diagnosis. The HSIL is the most associated with cronic Human Papilloma Virus (HPV) infection and can be related to other environment factors. As for dVIN, it’s more frequent in post-menopausal women with sclerosis lichen and it has a higher rate of progression to vulvar squamous carcinoma. The difference must be made in order to choose what is the best treatment, once there are various modalities, such as simple excision, CO2 ablation and topical application of imiquimod or fluoracil. This differences is also important for the development of measures that seek specific prevention, such as HPV vaccine for the HSIL and the proper treatment of vulvar conditions for the dVIN.


2019 ◽  
Vol 299 (3) ◽  
pp. 825-833
Author(s):  
Ferenc Zoltan Takacs ◽  
Julia Caroline Radosa ◽  
Florian Bochen ◽  
Ingolf Juhasz-Böss ◽  
Erich-Franz Solomayer ◽  
...  

BMC Cancer ◽  
2011 ◽  
Vol 11 (1) ◽  
Author(s):  
Nicolas Samartzis ◽  
Patrick Imesch ◽  
Konstantin J Dedes ◽  
Eleftherios P Samartzis ◽  
André Fedier ◽  
...  

Sign in / Sign up

Export Citation Format

Share Document